Peptigraph

Neuro & Cognition

DSIP (Delta Sleep-Inducing Peptide)

Why might this matter to you? If you struggle with sleep problems or chronic stress, you may come across DSIP: a naturally occurring small protein molecule made of 9 amino acids (a so-called nonapeptide) that may play a role in sleep. It was first isolated in 1974 from the cerebral blood of sleeping rabbits, and is researched today mainly for its delta-sleep-promoting, stress-regulating and neuroprotective effects (i.e. protecting brain nerve cells).

Also seen on labels, in price lists and in the community as: DSIP, DS

Editorial team ·Updated ·7 Sources ·evidence-rated ·independent & ad-free

Common use studies and practice

How this peptide is typically used - described, not recommended.

How much
100-500 µg per dose
How often
3-7 times a week
How long
2-8 weeks straight, then a 8-week break
Administration
Injection

For DSIP, user reports and clinic websites mention 100 to 500 micrograms (mcg) per injection, given subcutaneously (under the skin), 30 to 60 minutes before bedtime. They report daily doses, 5 days a week, or 3 times a week, often as an 8-week cycle followed by an 8-week break. Reviewed studies do not support this: data from the 1980s describe an intravenous infusion (into a vein) of 25 nmol per kg (about 1.5 to 3 mg for a 70 kg person), which cannot be applied to an injection.

Convert this to your own vial

The injection calculator tells you how many units that is on your syringe for your vial size. The injection manager keeps track of your mixed vial and every dose you log.

Open injection calculator → Track your vial in the injection manager

As of

DSIP is a tiny protein molecule (a peptide) found in the brain that has been researched since the 1970s as a possible regulator of sleep and stress. The name stands for 'Delta Sleep-Inducing Peptide', roughly 'a peptide that triggers delta sleep'.

DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide, a small protein molecule made of exactly 9 amino acids, with the sequence WAGGDASGE. It was first isolated in 1974 by the Basel group of Schoenenberger and Monnier from the cerebral venous blood of sleeping rabbits. It is one of the earliest 'sleep peptides' in neuroscience and remains of research interest for its delta-sleep-promoting, stress-regulating and neuroprotective actions (i.e. protecting brain nerve cells).

What is DSIP biochemically?

  • 9 amino acids, molecular weight ~849 Da
  • Very unstable in vitro (i.e. in the test tube): half-life of only about 15 minutes because the peptide is quickly broken down by the body's own degrading enzymes, called aminopeptidases. In the body it is likely bound to carrier proteins that stabilise it.
  • Gene, precursor protein and specific receptor (the matching docking site on cells) have not yet been identified
  • Regulated by glucocorticoids (the body's own stress hormones, such as cortisol) and shares similarities with a stress-related protein called GILZ

How does DSIP work?

In the brain, DSIP appears to have a calming effect and helps coordinate the interplay between sleep and stress.

More specifically, it is thought to act via NMDA receptors (excitatory docking sites on nerve cells) and α1-adrenergic receptors (docking sites that respond to stress signals), modulating the MAPK cascade, a cellular signalling chain through which cells respond to stimuli. It lowers basal corticotropin release (a stress-hormone precursor) and influences nocturnal N-acetyltransferase activity in the pineal gland (a tiny brain organ that also controls the sleep hormone melatonin), thereby coupling the sleep-wake rhythm with the stress response.

What effects have been studied?

  • Sleep: Induces spindle and delta EEG activity, i.e. slow brain waves of deep sleep, in animal models without suppressing REM phases
  • Stress and adaptation: Stress-protective, anti-seizure (anticonvulsant) and immune-balancing (immunomodulating) effects in several rodent studies
  • Stroke: A 2021 rat study (Tukhovskaya et al.) showed accelerated motor recovery after a localized stroke (focal ischemia)
  • Anaesthesia: Alters the BIS index (a measure of anaesthetic depth), EEG and heart rate variability as an adjunct to the anaesthetic isoflurane (Pomfrett 2009)

What does the human evidence say?

Several small, partly placebo-controlled trials (i.e. studies using a dummy drug as comparison) from the 1980s and 90s (Schneider-Helmert, Monti, Bes) have tested DSIP in chronic insomnia. Results are mixed: some patients showed improved sleep continuity, others showed no clear benefit. There is still no approval by the FDA (US authority) or EMA (European authority) for any indication. DSIP remains investigational, meaning it is still being researched and is not an approved medicine.

How was DSIP dosed in studies?

Human insomnia studies used 25-50 nmol/kg as a slow intravenous infusion before sleep. For a 70 kg adult that equals roughly 1.5-3 mg of DSIP. This is purely informational from the published literature and not a dosage recommendation. Any use must remain under medical supervision.

How does DSIP fit with other peptides?

DSIP is often mentioned alongside CJC-1295 / Ipamorelin, since both interact with the sleep-wake cycle and nocturnal GH release (release of growth hormone, which pulses mainly during deep sleep). More broadly it belongs to the family of neuropeptides such as Selank and Semax, which also address sleep quality and stress regulation.

Key caveats

  • No approval by the FDA (US authority) or EMA (European authority)
  • Gene and receptor unknown, mechanism partly hypothetical
  • Very short blood half-life (plasma half-life - the substance is broken down very quickly), usually administered as infusion in studies
  • This article is information, not medical advice and not a recommendation to obtain or use DSIP

Evidence at a glance

Research status
The research on DSIP is primarily based on preclinical and animal models, as well as small, outdated human trials from the 1980s and 1990s. Preclinical research includes isolation and synthesis based on delta sleep enhancement in rabbits [5, 21], and various physiological effects observed in rats [1, 18, 20]. Human studies are limited to small clinical trials and pilot studies without modern, large-scale randomized controlled trials [1, 3, 6, 8]. Regarding approval status, there are no FDA-approved DSIP products. Emideltide, a compound derived from DSIP, is under FDA review but was rejected for addition to the Section 503A Bulk Drug Substances List for compounding by eligible pharmacies [19, 24].
Human evidence
Human evidence is limited to small, older studies. In healthy volunteers, the first human study applied synthetic DSIP to six subjects via slow intravenous infusion [2]. For chronic insomnia, a 1992 double-blind study of 16 patients found higher sleep efficiency and shorter sleep latency compared to placebo [3], while other studies showed sleep normalization and improvement after single and repeated administrations [8, 11, 12]. An open-label study of 7 patients with severe insomnia reported normalized sleep in 6 cases for 3-7 months, alongside improved daytime mood and performance [6]. A case report of a 47-year-old woman with delayed sleep phase insomnia showed a 5-hour advance in main sleep phase and abrupt withdrawal of flunitrazepam after one week of treatment [13]. DSIP was also studied as an adjunct to isoflurane anaesthesia, altering bispectral index, EEG, and heart rate variability [14]. Additionally, clinical pilot studies investigated therapeutic effects in patients with chronic pain [15] and described multifunctional psychophysiological properties [9].
Dosages in studies & practice
In human clinical studies involving chronic insomniacs, DSIP was administered intravenously at a dose of 25 nmol/kg body weight before sleep [3, 8, 12]. In animal studies, specifically rabbit experiments, DSIP has been administered at 25 micrograms/kg intravenously and 1 mg/kg subcutaneously [22].
Risks & side effects
The provided sources do not contain specific information on the risks, side effects, or contraindications of DSIP. The only related information is a general lack of long-term safety data and references to safety and evidence gaps discussed by an FDA panel [24].
Research gaps
There are significant research gaps regarding DSIP. The bulk of primary human and animal research is outdated, published in the 1980s and 1990s, with no modern, large-scale randomized controlled trials or long-term safety data available [1, 3, 6, 8]. The mechanism of action remains an "unresolved riddle," with a 2006 review and a 1987 paper noting no convincing evidence for any proposed mechanisms [4, 18]. Furthermore, there are inconsistencies in animal studies, with some reporting sleep reduction rather than enhancement, such as in cats after intraperitoneal injection [17]. The quality of human evidence is also limited by very small sample sizes, open-label designs, and case reports [2, 3, 6, 13].

Editorial, sourced from primary literature - not medical advice.

Related peptides

Selank & Semax Cerebrolysin Oxytocin Semax

Sources

← Back to peptides

The Peptide Signal - monthly, ad-free Learn more